Sangivamycin

Research use only, not for human use.

Sangivamycin is an effective inhibitor of protein kinase C (PKC, Ki = 10 μM). Sangivamycin exhibits antiproliferative activity against a variety of human cancers.

Sangivamycin is an effective inhibitor of protein kinase C (PKC, Ki = 10 μM). Sangivamycin exhibits antiproliferative activity against a variety of human cancers.(In Vitro):Sangivamycin (0.3 μM; 0-72 hours) exhibits almost maximal cytocidal for MCF7/ADR or cytostatic for MCF7/WT effects. Sangivamycin activates caspases in MCF7/ADR cells. Upon exposure of MCF7/ADR cells to Sangivamycin (0.3 μM), a vast amount of cleavage of lamin A to a 28-kDa fragment is detected within 48 hours. Sangivamycin has differential antitumor effects in drug-sensitive MCF7/wild type (WT) cells, causing growth arrest, and in multidrug-resistant MCF7/adriamycin-resistant (ADR) human breast carcinoma cells, causing massive apoptotic cell death.

——

——

NSC 65346 | BA-90912

Cell Cycle/DNA Damage

Nucleoside Antimetabolite/Analog

——

——

——

18417-89-5

309.28

C12H15N5O5

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (323.33 mM)

NC(c1cn([C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)c2ncnc(N)c12)=O

——

(-20℃)

With Ice Pack

≥ 2 years